Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene DDR2
Variant L63V
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions DDR2 L63V lies within the discoidin domain of the Ddr2 protein (PMID: 22328973). L63V confers a gain of function to the Ddr2 protein, as demonstrated by increased Stat5 and Src phosphorylation (PMID: 22328973), elevated phosphorylation of Ddr2, and transformation activity in cell culture (PMID: 28161936).
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Transcript NM_001014796
gDNA chr1:g.162754625C>G
cDNA c.187C>G
Protein p.L63V
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001014796 chr1:g.162754625C>G c.187C>G p.L63V RefSeq GRCh38/hg38
XM_011509586 chr1:g.162754625C>G c.187C>G p.L63V RefSeq GRCh38/hg38
XM_006711344 chr1:g.162754625C>G c.187C>G p.L63V RefSeq GRCh38/hg38
XM_011509588 chr1:g.162754625C>G c.187C>G p.L63V RefSeq GRCh38/hg38
NM_006182 chr1:g.162754625C>G c.187C>G p.L63V RefSeq GRCh38/hg38
XM_011509587 chr1:g.162754625C>G c.187C>G p.L63V RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 L63V lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) prevented colony formation and induced cell death in lung squamous cell carcinoma cells expressing DDR2 L63V in culture (PMID: 22328973). 22328973
DDR2 L63V Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973). 22328973
DDR2 L63V Advanced Solid Tumor sensitive Nilotinib + Saracatinib Preclinical Actionable In a preclinical study, the combination of Saracatinib (AZD0530) with Tasigna (nilotinib) reduced Src and Stat5 activation and inhibited proliferation of transformed cells expressing DDR2 L63V in culture, with increased potency over either agent alone (PMID: 22328973). 22328973
DDR2 L63V Advanced Solid Tumor sensitive Dasatinib Preclinical Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973). 22328973
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DDR2 act mut lung non-small cell carcinoma sensitive Lucitanib Preclinical Actionable In a preclinical study, Lucitanib (E-3810) decreased DDR2 phosphorylation, and inhibited proliferation and induced apoptosis in lung squamous cell carcinoma cells harboring a DDR2 activating mutation in culture (PMID: 24696502). 24696502
DDR2 mutant lung squamous cell carcinoma sensitive Dasatinib Preclinical Actionable In a preclinical study, lung squamous cell cancer cells harboring DDR2 mutations demonstrated sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). 22328973
Molecular Profile Protein Effect Treatment Approaches
DDR2 L63V gain of function DDR2 inhibitor